Aleksandra Novikov1, Volker Vallon. 1. aDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, La Jolla bVeterans Affairs San Diego Healthcare System, San Diego cDepartment of Pharmacology, University of California San Diego, La Jolla, California, USA.
Abstract
PURPOSE OF REVIEW: The sodium glucose cotransporter 2 (SGLT2) reabsorbs most of the glucose filtered by the kidneys. SGLT2 inhibitors reduce glucose reabsorption, thereby lowering blood glucose levels, and have been approved as new antihyperglycemic drugs. Although the therapeutic strategy is very promising, many questions remain. RECENT FINDINGS: Using validated antibodies, SGLT2 expression was localized to the brush border of the early proximal tubule in the human kidney and was found upregulated in genetic murine models of type 1 and 2 diabetes. SGLT2 may functionally interact with the Na/H exchanger NHE3 in the proximal tubule. SGLT1-mediated reabsorption explains the fractional renal glucose reabsorption of 40-50% during SGLT2 inhibition. SGLT2 is expressed on pancreatic alfa cells where its inhibition induces glucagon secretion. SGLT2 inhibition lowers glomerular filtration rate in hyperfiltering diabetic patients consistent with the tubular hypothesis of diabetic hyperfiltration. New data indicate a potential of SGLT2 inhibition for renal medullary hypoxia and ketoacidosis, but also for blood glucose effect-dependent and independent nephroprotective actions, renal gluconeogenesis inhibition, reduction in cardiovascular mortality, and cancer therapy. SUMMARY: The findings expand and refine our understanding of SGLT2 and its inhibition, have relevance for clinical practice, and will help interpret ongoing clinical trials on the long-term safety and cardiovascular effects of SGLT2 inhibitors.
PURPOSE OF REVIEW: The sodium glucose cotransporter 2 (SGLT2) reabsorbs most of the glucose filtered by the kidneys. SGLT2 inhibitors reduce glucose reabsorption, thereby lowering blood glucose levels, and have been approved as new antihyperglycemic drugs. Although the therapeutic strategy is very promising, many questions remain. RECENT FINDINGS: Using validated antibodies, SGLT2 expression was localized to the brush border of the early proximal tubule in the human kidney and was found upregulated in genetic murine models of type 1 and 2 diabetes. SGLT2 may functionally interact with the Na/H exchanger NHE3 in the proximal tubule. SGLT1-mediated reabsorption explains the fractional renal glucose reabsorption of 40-50% during SGLT2 inhibition. SGLT2 is expressed on pancreatic alfa cells where its inhibition induces glucagon secretion. SGLT2 inhibition lowers glomerular filtration rate in hyperfiltering diabeticpatients consistent with the tubular hypothesis of diabetic hyperfiltration. New data indicate a potential of SGLT2 inhibition for renal medullary hypoxia and ketoacidosis, but also for blood glucose effect-dependent and independent nephroprotective actions, renal gluconeogenesis inhibition, reduction in cardiovascular mortality, and cancer therapy. SUMMARY: The findings expand and refine our understanding of SGLT2 and its inhibition, have relevance for clinical practice, and will help interpret ongoing clinical trials on the long-term safety and cardiovascular effects of SGLT2 inhibitors.
Authors: Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-09-21 Impact factor: 3.619
Authors: Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: J Bolinder; Ö Ljunggren; L Johansson; J Wilding; A M Langkilde; C D Sjöström; J Sugg; S Parikh Journal: Diabetes Obes Metab Date: 2013-08-29 Impact factor: 6.577
Authors: Henrik H Hansen; Jacob Jelsing; Carl Frederik Hansen; Gitte Hansen; Niels Vrang; Michael Mark; Thomas Klein; Eric Mayoux Journal: J Pharmacol Exp Ther Date: 2014-07-03 Impact factor: 4.030
Authors: Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2013-11-13
Authors: Valentin Gorboulev; Annette Schürmann; Volker Vallon; Helmut Kipp; Alexander Jaschke; Dirk Klessen; Alexandra Friedrich; Stephan Scherneck; Timo Rieg; Robyn Cunard; Maike Veyhl-Wichmann; Aruna Srinivasan; Daniela Balen; Davorka Breljak; Rexhep Rexhepaj; Helen E Parker; Fiona M Gribble; Frank Reimann; Florian Lang; Stefan Wiese; Ivan Sabolic; Michael Sendtner; Hermann Koepsell Journal: Diabetes Date: 2011-11-28 Impact factor: 9.461
Authors: Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi Journal: J Biol Chem Date: 2017-02-14 Impact factor: 5.157
Authors: Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2017-03-16 Impact factor: 8.237
Authors: K Melissa Hallow; Peter J Greasley; Gabriel Helmlinger; Lulu Chu; Hiddo J Heerspink; David W Boulton Journal: Am J Physiol Renal Physiol Date: 2018-07-18